Want to see JP:3349 full AI Analyst Report?
3349 Stock Chart & Stats
¥6699.00
¥109.00(1.60%)
At close: 4:00 PM EST
¥6699.00
¥109.00(1.60%)
Day’s Range― - ―
52-Week Range¥5,615.00 - ¥10,045.00
Previous CloseN/A
Volume659.40K
Average Volume (3M)399.89K
Market Cap
¥513.26B
Enterprise Value¥493.59B
Total Cash (Recent Filing)¥30.88B
Total Debt (Recent Filing)¥50.76B
Price to Earnings (P/E)15.9
Beta-0.24
Next Earnings
Oct 14, 2026EPS Estimate
105.98Next Dividend Ex-DateN/A
Dividend Yield1.27%
Share Statistics
EPS (TTM)395.96
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio4.18
Price to Book (P/B)1.63
Price to Sales (P/S)0.42
P/FCF Ratio-39.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥7,300.00Price Target Upside8.97% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)415.88
Revenue Forecast (FY)¥1.18T
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained top-line expansion demonstrates durable customer demand and successful store-level execution. A growing revenue base supports scale benefits in procurement and distribution, reducing per-unit costs and enabling reinvestment in stores and services over the medium term.
Conservative Balance SheetLow leverage and rising equity provide financial flexibility to fund expansion or withstand shocks. A conservative capital structure reduces refinancing risk and interest burden, supporting durable investment in store growth and pharmacy operations over multiple years.
Consistent ProfitabilityStable gross margins and growing absolute net income indicate a resilient retail model with predictable unit economics. Even modest operating margins can sustain returns when paired with scale, supporting steady earnings and operational planning over a multi-quarter horizon.
Bears Say
Weak Cash ConversionLow conversion of accounting profits to cash suggests working-capital absorption or non-cash income components, which constrains free cash available for dividends, buybacks, or debt reduction. Persistent weak conversion raises long-term funding and liquidity concerns.
Volatile Free Cash FlowIrregular and often negative FCF undermines the company's ability to self-fund expansion or cushion downturns. Reliance on external funding or asset sales for capex and growth can increase cost of capital and limit strategic optionality over several quarters.
Margin PressureSlim and declining net margins point to intensifying cost or pricing pressures in retail. Persistent margin compression reduces resilience to rising costs and limits reinvestment capacity, making long-term profitability sensitive to competitive and cost dynamics.
COSMOS Pharmaceutical Corporation News
3349 FAQ
What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?
COSMOS Pharmaceutical Corporation lowest stock price was ¥5615.00 and its highest was ¥10045.00 in the past 12 months.
What is COSMOS Pharmaceutical Corporation’s market cap?
COSMOS Pharmaceutical Corporation’s market cap is ¥513.26B.
When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?
COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Oct 14, 2026 which is in 85 days.
How were COSMOS Pharmaceutical Corporation’s earnings last quarter?
COSMOS Pharmaceutical Corporation released its earnings results on Jul 13, 2026. The company reported ¥117.31 earnings per share for the quarter, missing the consensus estimate of ¥117.372 by -¥0.062.
Is COSMOS Pharmaceutical Corporation overvalued?
According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Undervalued.
Does COSMOS Pharmaceutical Corporation pay dividends?
COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥42 which represents an annual dividend yield of 1.27%. See more information on COSMOS Pharmaceutical Corporation dividends here
What is COSMOS Pharmaceutical Corporation’s EPS estimate?
COSMOS Pharmaceutical Corporation’s EPS estimate is 105.98.
How many shares outstanding does COSMOS Pharmaceutical Corporation have?
COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.
What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?
COSMOS Pharmaceutical Corporation reported an EPS of ¥117.31 in its last earnings report, missing expectations of ¥117.372. Following the earnings report the stock price went up 0.11%.
Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?
Currently, no hedge funds are holding shares in JP:3349
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation manages an extensive network of drugstores throughout Japan. The company operates a significant 1,130 retail locations, strategically positioned across the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. Established in 1983, its primary office is situated in Fukuoka, Japan.
3349 Stock 12 Month Forecast
Average Price Target
¥7,300.00
▲(8.97% Upside)
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
Create SD Holdings Co., Ltd.
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―